GlycoNex In (4168) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 醣聯

GlycoNex In (4168) reported revenue of NT$11.9 million for Oct 2026. Revenue for Jan–Oct 2026 was NT$27 million (-19.4% year on year).

In Oct 2026, it ranked No. 132 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$11,000Nov 2024 NT$3 million24/11Dec 2024 NT$143,000Feb 2025 NT$13.6 million25/02Apr 2025 NT$665,000May 2025 NT$15.3 million25/05Jun 2025 NT$47,000Jul 2025 NT$29,00025/07Aug 2025 NT$3.3 millionSep 2025 NT$558,00025/09Dec 2025 NT$4.4 millionFeb 2026 NT$12.1 million26/02Apr 2026 NT$1.9 millionJul 2026 NT$1.1 million26/07Aug 2026 NT$91,000Oct 2026 NT$11.9 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$11.9 million——
Sep 2026NT$0-100.0%-100.0%
Aug 2026NT$91,000-97.2%-91.4%
Jul 2026NT$1.1 million+3,544.8%—
Jun 2026NT$0-100.0%—
May 2026NT$0-100.0%-100.0%
Apr 2026NT$1.9 million+185.7%—
Mar 2026NT$0—-100.0%
Feb 2026NT$12.1 million-11.2%—
Jan 2026NT$0—-100.0%
Dec 2025NT$4.4 million+2,979.7%—
Nov 2025NT$0-100.0%—
Oct 2025NT$0-100.0%-100.0%
Sep 2025NT$558,000-74.1%-82.9%
Aug 2025NT$3.3 million+17,089.5%+11,162.1%
Jul 2025NT$29,000+52.6%-38.3%
Jun 2025NT$47,000—-99.7%
May 2025NT$15.3 million+109,350.0%+2,204.2%
Apr 2025NT$665,000+731.3%—
Mar 2025NT$0—-100.0%
Feb 2025NT$13.6 million+47.2%—
Jan 2025NT$0-100.0%-100.0%
Dec 2024NT$143,000—-95.3%
Nov 2024NT$3 million—+27,390.9%
Oct 2024NT$11,000—-99.5%

Jan–Oct 2026 cumulative: NT$27 million (-19.4% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: GlycoNex In vs PEC / GlycoNex In vs Lotus Pharm / GlycoNex In vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

115年為委託研究收入。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16